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DPPC bilayerThe renin–angiotensin–aldosterone system (RAAS) plays a key role in the regulation of blood pressure. Renin is
the rate limiting enzyme of the RAAS and aliskiren is a highly potent and selective inhibitor of the human renin.
Renin is known to be active both in the circulating blood streamaswell as locally, when bound to the (pro)-renin
receptor ((P)RR). In this study we have investigated a possible mechanism of action of aliskiren, in which its ac-
cumulation in the plasma membrane is considered as an essential step for effective inhibition. Aliskiren's inter-
actions with model membranes (cholesterol rich and poor) have been investigated by applying different
complementary techniques: differential scanning calorimetry (DSC), Raman spectroscopy, magic angle spinning
(MAS) nuclear magnetic resonance (NMR) spectroscopy and small- and wide-angle X-ray scattering (SAXS and
WAXS). In addition, in silico molecular dynamics (MD) calculations were applied for further conﬁrmation of the
experimental data. Aliskiren's thermal effects on the pre- andmain transition of dipalmitoyl-phosphatidylcholine
(DPPC) membranes as well as its topographical position in the bilayer show striking similarities to those of an-
giotensin II type 1 receptor (AT1R) antagonists. Moreover, at higher cholesterol concentrations aliskiren gets ex-
pelled from the membrane just as it has been recently demonstrated for the angiotensin receptor blocker (ARB)
losartan. Thus, we propose that both the AT1R and the (P)RR-bound renin active sites can be efﬁciently blocked
bymembrane-bound ARBs and aliskirenwhen cholesterol richmembrane rafts/caveolae are formed in the vicin-
ity of the receptors.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Hypertension is a risk factor associatedwith cardiovascular diseases,
and the ﬁrst leading cause of death in economically developed coun-
tries. For this reason, medicinal chemists aim to synthesize more effec-
tive and novel drugs, which can regulate the blood pressure with longer
duration of action and fewer side effects. The most important system
which interferes with the regulation of pressure is the renin–angioten-
sin–aldosterone system (RAAS) [1,2]. RAAS activation is stimulated by a
drop in blood pressure, loss of blood volume or reduction in plasma so-
dium concentration. These signals trigger the release of renin, a highly
speciﬁc and selective aspartic protease, which cleaves angiotensinogen
(Aog) to produce the inactive decapeptide angiotensin I (AngI). AngI
is next converted by angiotensin-converting enzyme (ACE) to the active
peptide angiotensin II (AngII), which causes vasoconstriction when it, tmavrom@chem.uoa.grbinds to the angiotensin subtype 1 receptor (AT1R) or stimulates the se-
cretion of the hormone aldosterone. Since the rate-limiting step in this
cascade is determined by renin to produce AngI, inhibition of this step
is an effective therapeutic target against hypertension [3].
For many years, we are studying the interactions of AT1R antagonist
molecules or angiotensin receptor blockers (ARB) that prevent AngII to
exert its detrimental effects on AT1 receptor, with the lipid bilayers and
their receptor active site in order to comprehend their molecular basis
of action. ARBs are hypothesized to act on the AT1R by a two-step pro-
cess [4]. In the ﬁrst step the drug is incorporated into the membrane,
and in the second step it diffuses to the receptor site, where it binds to
the active site of the AT1R [5–7].
For renin, the situation is to some extent different [8]. Renin circulates
in the blood plasma, and thus a direct inhibition of renin in the systemic
system by aliskiren is possible. However, renin binds with a high afﬁnity
to the (pro)-renin receptor ((P)RR) [9–11], and subsequent studies
have shown that (P)RR-bound renin has a fourfold higher catalytic activ-
ity [12]. Thus a second, local mechanism of action of aliskiren is also pos-
sible (Fig. 1A). Due to its high lipophilicity (log P octanol/water = 2.45 at
pH 7.4 [13]) aliskiren is expected to accumulate as efﬁciently in lipid
Fig. 1.Molecular structures of aliskiren (A), DPPC (B), and cholesterol (C).
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therefore investigate the binding of aliskiren to different lipid bilayer
models (both, cholesterol poor and rich) and put the results in context
with the extensively studied AT1R antagonists for an improved under-
standing of the local interactions of aliskiren with (P)RR bound renin.
Cell plasmamembranes have a complex architecture hosting various
kinds of protein receptors which for the assembly of signalling mole-
cules are believed to get organized in cholesterol rich micro-domains
(rafts). Themost abundant lipid species in the lipid matrix of the vascu-
lar smooth muscle cells [18] and sarcolemma cardiac membranes [19]
are phosphatidylcholines (PCs). The most frequently found among
them are PCs with oleic and linoleic chains, and further dipalmitoyl-
phosphatidylcholine (DPPC). Hydrated DPPC bilayer models (poor and
rich in cholesterol) have been therefore applied to investigate
aliskiren-bilayer interactions (Fig. 1B and C) as they comprise very con-
venient mesomorphic states (gel, gel/ﬂuid and ﬂuid) and their thermal
as well as dynamic properties have been studied thoroughly [20].
In this context, we have initiated a new research activity that aims to
compare the membrane effects of aliskiren with those of AT1R antago-
nists, since both classes of molecules act in the same system and have
been used synergistically to affect the biomembrane and increase their
therapeutic index [21,22].
To undertake this task, we have studied interactions between drug
and lipid bilayers using differential scanning calorimetry, Raman spec-
troscopy, solid-state magic angle spinning (MAS) NMR spectroscopy
and small- and wide angle X-ray scattering. In addition, we have
complemented our studies using in silico MD simulations.
2. Materials and methods
2.1. Materials
Dipalmitoyl-phosphatidylcholine and cholesterol were purchased
from Avanti Polar Lipids (Birmingham, AL), and used without furtherpuriﬁcation. The salt form of aliskiren (aliskiren-hemifumarate) was
kindly supplied by Novartis (Basel).
2.2. Differential scanning calorimetry
For DSC experiments about 7 mg 50% (w/w) liposomal dispersions
were used. The aliskiren concentrations were 5, 10, 15 and 20 mol.%
and the cholesterol concentration varied from 12 to 15 mol.%. All sam-
ples were scanned from 25 to 50 °C at least three times until identical
thermal scans were obtained using a scanning rate of 2.5 °C/min. Fur-
ther details of the sample preparation, set-up and data analysis can be
found in our previous publications [14,16,17].
2.3. Raman spectroscopy
The samples' preparation for the Raman measurements was identi-
cal to that for DSC. Raman spectra were recorded with a Perkin-Elmer
GX Fourier Transform spectrometer (Shelton, CT). Raman spectra of
the examined samples were obtained in the frequency region of
3500–400 cm−1 and in the temperature range 25 to 50 °C. Further ex-
perimental details can be found in our previous publications [14–17].
2.4. MAS NMR
Sample preparation for solid-state NMR was identical to that for
DSC. The samples (20 μL) were transferred to 3.2 mm zirconia rotors.
13C MAS and 13C cross polarization (CP)MAS NMR spectra were obtain-
ed at 150.80 MHz with a 600 MHz Varian spectrometer (Palo Alto, CA).
The spinning rate usedwas 5 kHz. The experimental temperatureswere
25, 35, and 45 °C for CP/MAS experiments and 45 °C for the MAS mea-
surement. Chemical shifts were reported relative to 13C resonance of
tetramethylsilane. For both measurements the number of scans were
400 and the relaxation delay was 5 s. Polarization transfer in the CP/
MAS measurements was achieved with RAMP cross-polarization [23]
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continuous-wave hetero-nuclear proton decouplingwas applied during
acquisition.
2.5. X-ray scattering
The samples for theX-ray scattering experimentswere prepared in a
similar way as for DSC measurements. Time resolved simultaneous
small- and wide-angle X-ray scattering (SAXS andWAXS) experiments
were carried out at the Austrian SAXS beamline at ELETTRA, Trieste [24,
25]. The experimental details of the set-up and sample environment are
described in previousworks [14–17]. The samples were heated from 20
to 60 °C and back to 20 °C with a scan rate of 1 °C/min. Static exposures
were taken before and after each scan and their duration was 15 s.
In the time resolved X-ray scattering experiments, the d-spacings of
the gel and ﬂuid phaseswere derived by standard procedures [26,27]. In
particular cases, the SAXS patterns were analysed globally applying the
modiﬁed Caillé theory [28–30]. This globalﬁtting technique is described
in details elsewhere [31–34]. The headgroup-to-headgroup thickness,
dHH, and the bending ﬂuctuation (Caillé parameter),
η ¼ πkBT
2d2 √ KCBð Þ
ð1Þ
were directly obtained from the ﬁts (KC, denotes the membrane bend-
ing rigidity, B the compression bulk modulus, kB the Boltzmann con-
stant, T the temperature and d the lattice spacing).
2.6. Molecular dynamics
Aliskiren topology ﬁles were produced by PRODGR server. A bilayer
of 128 dimyristoyl-phosphatidylcholine (DMPC) and another with
DPPC molecules were simulated with a united atom representation
and the topology ﬁles were downloaded from the Tieleman Web
page [35–37], while 3655 water molecules were described by the Sim-
ple Point Charge (SPC) model. Three different concentrations of
aliskiren were simulated i.e., 1 (equal to 0.8 mol.%), 5 (4 mol.%) and
11 (8 mol.%) molecules, which are all placed initially in the aqueous
phase. Each system was energy-minimized using the steepest descent
method and next themolecular dynamics (MD) simulations were com-
menced for 250 ns. All simulations were performed with the MD pack-
age GROMACS 4.5.1 [36,38–40]. Equations of motion were integrated
with a 2 fs time step and all bondswere constrained to their equilibrium
length with the LINCS algorithm. The temperature was kept constant at
325 K using the Berendsen thermostat with a 0.1 ps coupling time con-
stant, while the Berendsen barostat was employed for the semi-
isotropic pressure coupling of the bilayer at 1 bar. For the non-bonded
interactions of the system, a cut-off radius of 10 Å was applied with
pressure and energy correction terms due to the truncation of the po-
tentials. The PME technique was used for the treatment of long range
electrostatics.Table 1
Representative diagnostic thermal effect values for DPPC and DPPC/cholesterol bilayers
without or with aliskiren.
Samples Tm
(°C)
ΔTm
(°C)
ΔH
(kcal/mol)
DPPC 41.20 ± 0.1 0.9 ± 0.1 7.33 ± 0.08
DPPC/aliskiren 95:5 40.93 ± 0.1 1.6 ± 0.1 7.86 ± 0.08
DPPC/aliskiren 90:10 39.08 ± 0.1 0.9 ± 0.1 9.46 ± 0.09
DPPC/aliskiren 85:15 38.13 ± 0.1 1.1 ± 0.1 10.04 ± 0.10
DPPC/aliskiren 80:20 38.34 ± 0.1 1.5 ± 0.1 10.45 ± 0.10
DPPC/cholesterol 85:15 40.60 ± 0.1 1.0 ± 0.1 5.12 ± 0.05
[DPPC/cholesterol 85:15]/aliskiren 95:5 37.97 ± 0.1 1.5 ± 0.1 6.47 ± 0.06
[DPPC/cholesterol 85:15]/aliskiren 80:20 36.80 ± 0.1 1.9 ± 0.1 7.33 ± 0.07The deuterium order parameter (Scd) of the alkyl tails is given by the
following equation:
−SCD ¼
2
3
Sxx þ
1
3
Syy ð2Þ
in which:
Si j ¼
1
2
3 cosθi cosθ j−δi j
D E
ð3Þ
Details on how the components are computed can be found in other
studies [36,38].
3. Results
3.1. Differential scanning calorimetry
The thermal changes of the DPPC and DPPC/cholesterol bilayers in
the absence and presence of aliskiren have been analysed in DSC mea-
surements (see Supporting Information, Fig. S1). In Table 1 the quanti-
tative data of the diagnostic parameters (Tm, ΔΤm, and ΔΗ) are
presented. In pure DPPC, both the pre-transition (lamellar gel phase,
Lβ′ [41] to the ripple phase, Pβ′ [42]) as well as themain-transition (for-
mation of the ﬂuid lamellar phase, Lα [43]) are observed. The recorded
transition temperatures (Tpre = 37.6 ± 0.3, ΔTpre = 1.0 ± 0.3, Tm =
41.20 ± 0.1, ΔTm = 0.9 ± 0.1) and enthalpies (ΔHpre = 1 ± 0.02,
ΔH= 7.33 ± 0.08) for pure DPPC bilayers are in good agreement with
literature values [20].Fig. 2. (A) I1090/I1130 vs. temperature plots for pure DPPC ( ), DPPC containing 20mol.% of
aliskiren ( ), DPPC containing 15 mol.% cholesterol ( ) and [DPPC/cholesterol (85/15)]/
aliskiren (80/20) ( ). The same symbolic is used for panel B representing I2850/I2880 vs.
temperature plots.
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main phase transition and abolishes the pre-transition without causing
signiﬁcant effect on the phase transition temperature, Tm, and on the en-
thalpy, ΔΗ. The use of the higher concentrations of aliskiren (10–20
mol.%), results in a further progressive decrease of Tm and an increase
ofΔΗ. Two concentrations of aliskiren (5 and 20mol.%)were used to ex-
amine its thermal effects on DPPC/cholesterol bilayers. In both cases the
pre-transition gets suppressed, while the main phase transition
broadens, Tm decreases slightly and ΔΗ decreases (Table 1).3.2. Raman spectroscopy
Raman spectra of pure DPPC, DPPC/aliskiren (80/20), DPPC/choles-
terol (85/15), and [DPPC/cholesterol (85/15)]/aliskiren (80/20) bilayers
were obtained in a temperature range of 25–50 °C. Spectral bands in
region from 1000 to 1150 cm−1 are related to the hydrocarbon skeletal
C–C stretching modes. In particular, the bands at ~1090 cm−1 and
~1130 cm−1 reﬂect the C–C stretching modes in gauche and trans con-
formations, respectively [16,17,44,45]. The C–H stretching bands at
~2850 cm−1 and ~2880 cm−1 are due to symmetric and antisymmetric
stretchingmodes in the methylene groups (CH2) of the alkyl chains, re-
spectively, while the ~2935 cm−1 band is correlated to the symmetric
C–H stretchingmode in the terminal methyl group [45–47]. The two in-
tensity ratios I1090/I1130 and I2850/I2880 (Fig. 2) reﬂect the transition be-
haviour of the different bilayers studied and in particular describe the
ﬂuidity of the membranes. How aliskiren inﬂuences the order/disorder
of the different model membranes is discussed in Section 4.1.Fig. 3.Observed chemical shifts for the carbons of DPPC in 13C CP/MAS spectra at 25, 35 and 45
cholesterol (85:15)]/aliskiren (80:20) bilayers.3.3. MAS NMR
To obtain a detailed local information on the incorporation of
aliskiren and cholesterol in the DPPC bilayers, we applied high resolu-
tion 13C MAS and CP/MAS NMR spectroscopy [48] (Fig. 3). Observed
chemical shifts for the carbons of DPPC are summarized in Table 2 for
DPPC, DPPC/cholesterol (85/15), DPPC/aliskiren (80/20), and [DPPC/
cholesterol (85/15)]/aliskiren (80/20) bilayers (see also Supporting In-
formation Tables S1 and S2). The spectra are presented according to
the (i) headgroup, (ii) glycerol backbone, (iii) esteriﬁed carbonyl, and
(iv) hydrophobic lipid chain regions (for carbon identiﬁers of DPPC bi-
layers refer to Fig. 1B).
3.3.1. Head-group region
Minor changes are observed for the four preparations in the
headgroup region (N(CH3)3, C-2‴and C-2‴). The head-group conforma-
tional changes from gel to liquid crystalline phase are less pronounced
compared to those observed in the hydrophobic lipid chain region (cp.
Section 3.3.4). Further also the presence of aliskiren and cholesterol
causes onlyminor chemical shift increases (maximumdown ﬁeld effect
of 0.13 ppm). Indeed, chemical shifts of DPPC/aliskiren, DPPC/cholester-
ol and DPPC/cholesterol and DPPC/aliskiren preparations are alike, indi-
cating that cholesterol and aliskiren are affecting the headgroup region
similarly.
3.3.2. Glycerol backbone region
A downﬁeld shift was observed during the phase transition from the
gel to liquid crystalline state for the four different membrane models°C for (A) DPPC, (B) DPPC/cholesterol (85/15), (C) DPPC/aliskiren (80/20), and (D) [DPPC/
Table 2
Observed chemical shifts for the carbons of DPPC in 13CΜΑS and CP/MAS spectra in a temperature range of 25–45 °C.
Glycerol carbons Carbonyl carbons Hydrophobic chain region Headgroup region
T (°C) Sample C-1 C-2 C-3 C-1′,
C-1″
C-2′,
C-2″
C-3′,
C-3″
(CH2)′10,
(CH2)″10
C-14′,
C-14″
C-15′,
C-15″
C-16′,
C16″
N(CH3)3 C-2‴ C-1‴
13C-MAS
45 DPPC 63.80 71.41 64.41 174.02 34.81 25.86 31.10 32.83 23.41 14.49 54.89 66.82 60.21
45 DPPC/cholesterol (85/15) 63.88 71.45 64.53 174.19 34.93 26.04 31.51 33.00 23.54 14.55 54.93 66.84 60.28
+174.00
45 DPPC/aliskiren (80/20) 63.93 71.53 64.59 174.20 34.91 25.90 30.92 32.85 23.47 14.64 54.98 66.95 60.32
25.76 30.35
45 [DPPC/cholesterol (85/15)]/aliskiren (80/20) 63.92 71.48 64.59 174.20 34.91 25.90 30.96 32.85 23.47 14.64 54.95 66.93 60.30
25.75 30.36
13C CP/MAS
25 DPPC – 71.22 64.38 172–174 34.98 26.72 33.25 34.22 24.44 14.65 54.76 66.63 60.22
24.17
25 DPPC/cholesterol (85/15) – 71.22 64.48 172–174 35.15 26.82 33.26 34.26 24.48 14.70 54.79 66.66 60.26
24.15
25 DPPC/aliskiren (80/20) 63.85 71.29 64.50 173–175 35.16 26.57 33.31 34.62 24.64 (15.06) 54.79 66.76 60.23
32.19 24.90 14.65
25 [DPPC/cholesterol (85/15)]/aliskiren (80/20) 63.83 71.33 64.52 173–175 35.22 26.63 33.32 34.65 24.68 (15.09) 54.81 66.74 60.25
24.91 14.61
35 DPPC – 71.14 64.38 172–175 35.10 26.37 33.11 – 24.25 14.60 54.79 66.69 60.20
35 DPPC/cholesterol (85/15) – 71.21 64.47 172–175 35.19 26.46 33.10 – 24.29 14.65 54.92 66.81 60.33
35 DPPC/aliskiren (80/20) 63.95 71.51 64.62 174.21 34.96 25.89 31.06 33.30 24.60 (15.12) 54.98 66.94 60.34
30.46 32.93 23.55 14.71
35 [DPPC/cholesterol (85/15)]/aliskiren (80/20) 63.91 71.44 64.59 174.17 34.91 25.90 31.00 32.89 23.53 14.66 54.93 66.87 60.31
30.42
45 DPPC 63.77 71.37 64.49 174.03 34.81 25.85 31.06 32.79 23.39 14.49 54.86 66.81 60.19
45 DPPC/cholesterol (85/15) 63.86 71.43 64.55 174.17 34.93 26.02 31.43 32.97 23.53 14.55 54.93 66.85 60.27
45 DPPC/aliskiren (80/20) 63.93 71.53 64.56 174.16 34.93 25.87 30.89 32.82 23.48 14.63 55.00 66.97 60.32
25.76 30.32
45 [DPPC/cholesterol (85/15)]/aliskiren (80/20) 63.93 71.48 64.58 174.18 34.92 25.88 30.92 32.83 23.46 14.63 54.97 66.95 60.31
25.76 30.34
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stability in this bilayer region (C-1, C-2, C-3). Cholesterol causes down-
ﬁeld changes up to 0.1 ppm, when comparing DPPC/cholesterol and
DPPC bilayers at the same temperatures. When the DPPC/aliskiren and
DPPC bilayers are compared, higher downﬁeld shifts reaching
0.37 ppm are observed. DPPC bilayers containing both aliskiren and
cholesterol show similar chemical shifts with those containing DPPC
and aliskiren.
3.3.3. Carbonyl region
The resolution for C-1′ in the four preparations was not sufﬁcient
to follow the chemical shift changes during the phase transition. For
C-2′ a biphasic effect was observed, i.e., a downﬁeld effect in the
ripple phase and an upﬁeld effect in the ﬂuid lamellar phase. For C-
3′ a progressive upﬁeld effect (decrease of chemical shift) was emi-
nent as the temperature increases reaching 0.7 ppm in the Lα
phase, indicating that this carbon in the carbonyl region behaves
similarly to all other carbons at the hydrophobic region. Similar ef-
fects were observed for the DPPC/cholesterol sample. In DPPC/
aliskiren bilayers a progressive upﬁeld effect (b1 ppm)was observed
for C-3′ and C-2 . Similar upﬁeld effect (b1 ppm)was also obtained in
the case that both aliskiren and cholesterol are incorporated in the
DPPC bilayers, i.e., DPPC/aliskiren and DPPC/cholesterol/aliskiren bi-
layers showed similar chemical shifts.
3.3.4. Hydrophobic lipid chain region
The chemical shifts decrease when DPPC bilayers undergo the
transition from the lamellar gel phase Lß′ (25 °C) towards the ripple
phase Pß′ (35 °C) and lamellar liquid crystalline phase Lα (45 °C).
This is due to the strong trans–gauche isomerization effects observed
especially in the turnover to the Lα phase. Upﬁeld effect of the
carbons which constitute the hydrophobic region was also observed
in DPPC/cholesterol and DPPC/aliskiren bilayer samples. The mostpronounced upﬁeld effect was with (CH2)′10 carbons reaching al-
most 3 ppm while with C-16 , C-15 and C-14 the effect was ranging
between 0.02 and 1.40 ppm.
3.4. X-ray scattering
In Fig. 4 an overview of the time-resolved SAXS/WAXS experiments
is presented. In the contour plots high scattering intensities are colour-
coded with red and orange, while lower scattering intensities are given
in green and blue.
The structural changes in pure DPPC bilayers [49] are exempliﬁed in
Fig. 4A. At ambient temperatures the lamellar gel phase (Lβ′) is ob-
served. The chains are packed in an orthogonal lattice [44,45] and tilted
with respect to the bilayer plane about 32° [50]. Thereafter, the stable
ripple phase (Pβ′) forms, followed by the lamellar ﬂuid phase (Lα).
Note, that the transition is not reversible, but in cooling direction two
ripple phases form: the stable and the so-called metastable ripple
phase (Pβ′ and Pβ′ mtstbl) [51]. The interaction of 10 mol.% cholesterol
with phosphatidylcholine bilayers is presented in Fig. 4B. Both in the
gel and the ﬂuid phase regime cholesterol induces in part a liquid or-
dered (lo) phase, where the lipids are free to laterally diffuse, but at
the same time exhibit a certain chain order [52–54].
As can be seen in the SAXS patterns in Fig. 4C, aliskiren provokes in
the gel phase the onset of an unbinding of the bilayers. The ﬁrst order
diffraction peak is centred at s = 0.007 Å−1, which corresponds to a
d-spacing of about 140 Å. This means that the bilayers are about 100 Å
apart. In otherwords themultilamellar vesicles (MLVs) are highly swol-
lenwithwater. In the ﬂuid phase regime the unbinding of bilayermem-
branes is complete, i.e., the bilayers are spatially uncorrelated.
In contrast to the effect of aliskiren alone, the incorporation of
aliskiren together with cholesterol in the DPPC bilayers reduces the d-
spacing drastically from 140 to 72 Å (Figs. 4D and 5B). The d-spacing
of 72 Å in the lamellar gel-phase can actually be explained by a loss of
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layer thickness, dHH, of 50 Å deduced from the electron density proﬁle of
the bilayer (Supporting Information Figs. S2–S3 and Table S3; note that
a complete loss of chain tilt would result in a d-spacing of about 72 Å
[48]). However, in the ﬂuid phase a coexistence of highly swollen
MLVs (maximum d-spacing is 102 Å, Fig. 5B) together with a high frac-
tion of spatially uncorrelated bilayers is observed.
The temperature dependent lipid chain packing of the four different
studied samples is presented in Fig. 6. The lipid chain packing gives a
relatively good indication for Tm. Themelting point for pure DPPC bilay-
ers is determined with the WAXS recordings to be at 43 °C, while with
decreasing lipid concentration the melting point is observed at 42, 40
and 38 °C, respectively. This is readily understood, since an increasing
concentration of impurities in the form of cholesterol and/or aliskiren
reduces the overall van der Waals energy. Another effect can be ob-
served in the packing density of the lipid chains in the gel phase. For in-
stance, at 37 °C the ﬁrst order diffraction peak indicates an averaged
nearest neighbour distance of the lipid chains of 4.27 Å for DPPC bilayers
(area per chain 21.0 Å2). Aliskiren alone has a condensing effect (d =
4.20 Å at 37 °C), whereas 10 mol.% cholesterol causes an overall looser
chain packing in the gel phase: the d-spacing is about 4.31 Å in both
the DPPC/cholesterol as well as the DPPC/aliskiren/cholesterol bilayer
systems. This is understood, since cholesterol above a certain threshold
(typically N5mol.%) induces in part the lo-phase, in which the apparent
area per lipid is enhanced.
3.5. Molecular dynamics
The effect of aliskiren molecules on DMPC and DPPC model mem-
branes was examined with MD simulations at three differentFig. 4. Temperature scan ofmultilamellar vesicles of (A)DPPC from20 to 60 °C and back to 20 °C
themaximum temperaturewas reached at frame40. For the phase assignments refer to themai
(90/10)]/aliskiren (80/20).concentrations of the drug, i.e., for one, ﬁve and eleven molecules per
128 lipids (0.8, 4 and 9mol.%). The density proﬁles of all individual com-
ponents in the system along the axis orthogonal to the bilayer (z-axis)
are depicted in Fig. 7. Obviously aliskiren molecules diffuse into the in-
terior of the bilayer even though their initial positions in the simulations
were given in the aqueous phase.
Another important property of a lipid-bilayer system is the area per
lipid which may be estimated by a variety of experimental techniques
(e.g., NMR, X-ray diffraction). Most of the experimental values lie be-
tween 61 and 67 Å2/lipid indicating that the membrane is in the liquid
crystalline phase. Similar results are obtained by our simulations as
listed in Table S4. Moreover, there is an increase for the area per lipid
as more aliskiren molecules are added. Focusing on the headgroup of
lipids, the angle between the vector connecting P and N atoms and the
z-axis is important. The presence of aliskiren does not affect the values
of the angle as seen in Table S4. Furthermore, the radial distribution
function (RDF) betweenwater oxygen and phosphate oxygenwas com-
puted to evaluate the inﬂuence of the drug on the interface between
DPPC and aqueous phase. No signiﬁcant effect was observed by the
aliskiren on the RDF (Fig. 7C).
The order parameters of DMPC bilayers are presented in Fig. 8A and
are in agreementwith reported data using 2H solid state NMR spectros-
copy [55,56]. They were averaged over the two alkyl tails of DMPC and
clearly show upward shifting as the number of drugmolecules increase.
Fig. 8B instead represents the change of order parameter as the number
of loaded aliskiren molecules varies from 1 to 11. Accordingly, the
highest change in the order parameter occurs in carbon numbers of 6
to 9 (highlighted region in Fig. 10B). The results suggest that the
aliskiren molecules mainly sit at the middle of the hydrophobic tails of
the lipid. Note that both aliskiren simulation sets on DMPC and DPPCwith 1 °C/min. Note that at frame numbers 1 and 80 the sample temperaturewas 20 °C and
n text. (B) DPPC/cholesterol (90/10), (C)DPPC/aliskiren (80/20) and (D) [DPPC/cholesterol
Fig. 5.The scatteringproﬁles of A)DPPC/aliskiren and B)DPPC/cholesterol/aliskiren at two
different temperatures. The proﬁles corresponding to the dashed lines are indicated in
Fig. 4C andD. The solid lines are the globalﬁts of the SAXSdata (see Section 2.4). Addition-
ally, the electron density map of the DPPC/cholesterol/aliskiren bilayer at 20 °C has been
determined (see Supporting Information Figs. S2–S3 and Table S3).
990 A. Sadeghpour et al. / Biochimica et Biophysica Acta 1848 (2015) 984–994bilayers display very similar results, i.e., demonstrating that a small
change in chain length does not have a signiﬁcant inﬂuence on the in-
corporation of aliskiren.Fig. 6. Lattice spacing of the ﬁrst order diffraction peaks of DPPC (black), DPPC/cholesterol
(90/10) (green), DPPC/aliskiren (80/20) (red), and of [DPPC/cholesterol (90/10)]/aliskiren
(80/20) (blue) bilayers. TheWAXS analysis displays thenearest neighbour chain to chain dis-
tances derived from the ﬁrst order diffraction peaks in the gel phase and rough distances are
determined from the position of the diffuse scattering maximum in the ﬂuid phase.4. Discussion
4.1. Bilayer interactions with aliskiren
According to the differential scanning calorimetric data, aliskiren at
5 mol.% broadens signiﬁcantly the ΔT1/2 showing that this low concen-
tration acts as an “impurity”. At higher concentrations, aliskiren pro-
gressively lowers the phase transition temperature and increases ΔΗ,
while it affects lessΔT1/2. Similar increases in theΔΗ, at high concentra-
tions (N10 mol.%) have also been observed for the AT1R antagonists
losartan, irbesartan, valsartan and candesartan cilexetil, but not for
candesartan. In addition, this progressive broadening of the phase tran-
sition and abolishment of the pretransition was more eminent to
losartan, valsartan and candesartan cilexetil, but not for candesartan
[16,17,57]. This increase of ΔΗ, has been interpreted in our previous
publications to be associated with partial interdigitation of the lipid
chains in the gel phase. In fact the SAXS results of DPPC/aliskiren bilay-
ers at 20 °C support this probable cause: the membrane thickness, dHH,
decreases from44Å for pureDPPC bilayers to about 31Å in the presence
of aliskiren (Fig. 9A).Intramolecular trans–gauche conformational changes within the hy-
drocarbon chain region can be monitored directly by the intensity ratio
I1090/I1130 in Raman spectroscopy. This intensity ratio at this peak height
allows the direct comparison of the bilayer disorder–order transitions
between liposome preparations without or with drug incorporation. In
Fig. 2A the changes in Raman ratio of I1090/I1130 are presented. The tran-
sition temperatures are well consistent with the results from the calori-
metric measurements. DPPC bilayers show a strong increase in Raman
ratio across the gel to liquid crystalline phase (ΔΙ = 0.58), which
means risingupof about 80%. Incorporation of aliskiren into these bilayers
induces higher disorder in gel phase and less disorder in ﬂuid phase,
when compared to the pure DPPC bilayers system. Note, the increase of
this Raman ratio across the gel to liquid phase is only about 22% (from
0.88 to 1.1). The intensity ratio I2850/I2880 (Fig. 2B) describes the main
change occurring in the hydrocarbon-chain region of the lipids and corre-
sponds to intermolecular interactions among aliphatic chains [58]. It is
sensitive to subtle changes in conformational order from rotations,
kinks, twists and bends of the lipid chains [59]. Alike to the ratio I1090/
I1130 the presence of aliskiren causes signiﬁcant increase in the I2850/I2880
meaning that drug loading causes disorder in the lipid bilayers in the
gel phase. Thus, consistently the two ratios show that aliskiren causes ﬂu-
idization of the lipid bilayers. However, the Raman spectroscopy results
showdistinct differences between the effects of aliskiren in DPPC bilayers
as compared to AT1R antagonists. Aliskiren increases the trans–gauche
ratio to a lesser extent than ARBs (e.g., olmesartan increases that ratio
with signiﬁcantly stronger extent, i.e. from 0.9 to 1.7 [16]).
Fig. 8. A) Deuterated order parameters for the alkyl tails of DMPC in presence of aliskiren
molecules as obtained from the MD simulations. B) Difference in the order parameter be-
tween the alkyl chains of highest and lowest loaded aliskiren.
Fig. 7. Molecular dynamics simulations of aliskiren DPPC membrane interactions.
A) Snapshot of aliskiren in the DPPC bilayer (128 lipids, 3655 water molecules).
B) Density proﬁles along the z-axis of the DPPC bilayer for the system with 11 aliskiren
molecules. C) Phosphate oxygen to water oxygen radial distribution function for the
three different concentrations of aliskiren molecules.
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while the 13C CP/MAS spectra of this region were not as eminent
(Fig. 2). At 35 °C, the ﬁndings reveal a narrowing of the peaks in aliskiren
loaded membranes as compared to the DPPC bilayers alone, indicating a
change in ﬂuidity of the lipid bilayers in the ripple phase regime (Pβ′
phase). When AT1R antagonists or aliskiren is present, this phase gets
suppressed, which is in agreement with DSC results. However, there is
an exception to the rule, the ARB olmesartan does not cause an abolish-
ment of the pre-transition and no narrowing of the peaks at 35 °Cwas ob-
served indicating the complex motions of the lipids existing in the Pβ
phase.The interdigitation effect induced by aliskiren can be further corrob-
orated by the X-ray diffraction data. As presented in the results section
(Fig. 5A), the head–head distance (dHH) is about 31.4 Å in the presence
of aliskiren. This value is far smaller compared to the dHH value of 44.2 Å
for pure DPPC bilayers [43]. Accordingly, one may conclude that the
chain tilt loss is accompanied by the interdigitation of the hydrophobic
layer by about 13 Å (Fig. 9A). Consequently, one expects the area per
lipid to increase, and this is exactly what the MD simulations data con-
ﬁrm as the aliskiren concentration increases (Table S4).
Another apparent effect of aliskiren is the induction of strong water
swelling of the MLVs, i.e. the bilayers separation increases from 19 to
100 Å at 20 °C and from 28 to 130 Å at 60 °C (Fig. 9). Note also, that ac-
tually only a small fraction of the membranes remain spatially correlat-
ed in the ﬂuid phase, while the biggest fraction of bilayers completely
unbinds (cp. Fig. 5). In contrast in the gel phase the main fraction of
the sample remains ordered. Here the swelling can be explained by
electrostatic repulsion induced by the positively charged aliskiren mol-
ecules at pH 7 (aliskiren has only one pKa value of 15.9, and hence has
strong basic proprieties [60]; note membrane undulations usually play
a minor role in the gel phase). In the ﬂuid phase instead both electro-
static repulsion as well as the onset of membrane undulations will con-
tribute to the increase in bilayer separation. This means that above the
melting point the onset of Helfrich-undulations of the membranes de-
livers one part of the explanation. However, the electrostatic repulsion
force is expected to diminish above Tm. As long as the partition coefﬁ-
cient of aliskiren can be assumed to be temperature independent, then
this force diminishes in the ﬂuid phase, simply because the surface
charge density decreases (note, the area per lipid increases above Tm).
Thus, both increased membrane undulations and a higher partition
Fig. 9. Schematic representation of the pure DPPC, DPPC/cholesterol, DPPC/aliskiren and DPPC/cholesterol/aliskiren bilayers. For all four model membrane systems two adjacent bilayers
are shown at 20 °C (A) and at 60 °C (B), respectively. Cholesterol molecules are coloured in green and aliskiren in red. Above each scheme the polar thickness (d-dHH) and below the d-
spacings are given. The data were derived from the SAXS data (see Section 3.4).
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dance with the given observations.
4.2. Location of aliskiren in the DPPC bilayers
Molecular dynamic simulations and NMR spectroscopy data have
been used to locate the topography of the aliskiren in the lipid bilayers.
The NMR data show almost no change in chemical shifts within the
headgroup and glycerol backbone and onlyminor changes in the chem-
ical shifts of the carbonyl region, when aliskiren is incorporated in DPPC
bilayers. However; drastic changes appeared in the hydrophobic lipid
chain regionwith itsmaximumat the carbon number 10. Thus, aliskiren
is mainly centred around this carbon, both in the gel and liquid phases.
Further, the MD simulations approve this ﬁnding (see the density pro-
ﬁles in Fig. 7B). We note, that Pomes and co-workers [61] pointed out
that water-defect and lipid surface reorganization processes for small
molecule may take as long as several microseconds. These long termFig. 10. Schematic representation of cholesterol-induced release of aliskiren and losartan.
Left hand side: aliskiren and losartan accumulate in the lipid bilayer, but not necessarily
inhibit the (P)RR and AT1R. Angiotensinogen (Aog) gets cleaved by (P)RR-bound renin
to angiotensin I (AngI), which by the angiotensin-converting enzyme (ACE) gets altered
to the active peptide angiotensin II (AngII). Right hand side: as soon as a cholesterol rich
caveolae is formed, aliskiren and losartan get released from the bilayer and block the
receptors.processes are not included in our MD simulations, however, aliskiren
places itself quite deep in the bilayer, where interfacial water-
restructuring mechanism plays a minor role. Moreover, order parame-
ter simulations demonstrate that aliskiren mainly accumulates at the
centre of the hydrophobic lipid chain (Fig. 8B; corresponding to the car-
bon numbers 7 to 11 in the DPPC given in Fig. 1B).
4.3. The inﬂuence of cholesterol
At 10 mol.% cholesterol content, both in the gel and the ﬂuid phase
regimes, cholesterol induces in part the liquid ordered (lo) phase caus-
ing a decrease ofΔH by 30% (Table 1). However, progressive addition of
aliskiren into the DPPC/cholesterol composites increasingly diminishes
the effect of cholesterol. Both aliskiren and AT1R antagonist losartan
act similarly against the lowering effect of ΔΗ caused by cholesterol
[62].
Furthermore, cholesterol itself induces a condensing effect in the
ﬂuid lamellar phase of DPPC bilayers. This is observed in the increase
of the Raman ratio at I1090/I1130 by only about 15%. However, addition
of cholesterol together with aliskiren causes a further increase of
Raman ratio during the main phase transition (ΔΙ = 1.55 − 0.96 =
0.59, Fig. 2A). The presence of aliskiren/cholesterol alike also causes sig-
niﬁcant increase in the I2850/I2880 ratio meaning that the presence of
these two components together causes disorder in the lipid bilayers
(Fig. 2B). Thus, it can be understood that aliskiren causes ﬂuidization
of the lipid bilayers even in the presence of cholesterol. This is also con-
ﬁrmed by the bilayer thicknesses deduced from the SAXS data at 60 °C.
The dHH values for DPPC/aliskiren and DPPC/cholesterol/aliskiren do not
differ signiﬁcantly.
From the NMR data, it can be shown that cholesterol abolishes the
pre-transition but, interestingly does not cause signiﬁcant changes in
the line-widths of the peaks (Fig. 3). This is an interesting observation
and points out that, more complex motions are observed in DPPC/cho-
lesterol bilayers as compared to DPPC/aliskiren or DPPC/cholesterol/
aliskiren complexes.
While we have observed that aliskiren's incorporation induces a
strong increase in the bilayer separations due to electrostatic repulsion,
this effect is reduced under the presence of 10mol.% cholesterol, i.e., we
observe again a convergence of adjacent bilayers (see Fig. 9 bottom). A
similar effect is apparent when losartan is interacting with DMPC/cho-
lesterol membranes [15]. Initially, unbound membranes start to realign
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Thus, it is tempting to assume that both losartan and also aliskiren get
expelled from cholesterol rich membranes. This would at least deliver
a straight forward explanation for the observed reduction in the bilayer
separation distance.
In this respect, we brieﬂy discuss a possible route of action of
aliskiren. Due to its high lipophilicity [13] aliskiren is expected to accu-
mulate as efﬁciently in lipid bilayers as the comprehensively studied
ARBs [14–17] (Fig. 10, left hand side). However, when cholesterol rich
domains (caveolae) would form in the direct vicinity of a (P)RR, then
membrane-accumulated aliskiren molecules are likely to get expelled
from the lipid bilayer due to the high concentration of cholesterol (cp.
Fig. 4C and D), and the binding of the inhibitors to the active site be-
comes possible from the extracellular ﬂuid (Fig. 10; right hand side).
The same scenario could occur also for the mechanism of action of
ARBs, i.e., also the AT1R could be efﬁciently blocked by for instance
membrane-bound losartans, when a cholesterol rich membrane caveo-
lae is formed. This newly proposed mechanism is also interesting in the
light of the increasingly investigated intracellular renin-angiotensin sys-
tem [10,63].
5. Conclusion
The interactions of aliskiren with cholesterol-rich and cholesterol-
poor plasmamembranemodels have been investigated both experimen-
tally (DSC, Raman spectroscopy, NMR, X-ray scattering) and byMD sim-
ulations. It turned out that aliskiren behaves inmany respects in a similar
fashion as the beforehand studied ARBs. Aliskiren incorporates in the bi-
layer with a high afﬁnity, but positions itself a bit deeper in the mem-
brane core as compared to most of the ARBs. Similarly, aliskiren
induces a partial interdigitation of the lipid chain in the gel phase. As a
consequence, already at low concentrations the pretransition of DPPC
gets suppressed. Moreover, the thermodynamic alterations (lowering
of Tm and increasing of themain transition enthalpy) and ﬂuidization ef-
fects on PC-model membranes have shownmany parallels to the action
of AT1R antagonists. Most interestingly, already the presence of 10mol.%
cholesterol expels aliskiren at least in part from the membrane. This has
led us to propose a reﬁned mechanism of action of aliskiren for the case
of its accumulation in the plasma membranes of e.g., vascular smooth
muscle cells.
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